In the realm of biotech manufacturing, the industrialization of stem-cell based therapies presents a unique set of challenges. The gap between research and commercialization necessitates scalable cell production platforms to meet the demand for therapeutic cell types. Human pluripotent stem cells (hPSCs) serve as a crucial source material for generating these therapeutic cells, requiring innovative solutions to ensure efficient and reliable production at scale.
The journey from research to commercialization involves various stages, each demanding specific quantities of cells. To bridge this gap, a closed, automated, and scalable stirred tank bioreactor platform has been developed to support high fold expansion of hPSCs. This platform integrates in-process monitoring and online systems to streamline operations, reduce labor requirements, and mitigate contamination risks. The expansion process involves controlled bioreactor cultivation using perfused xeno-free media, followed by harvest, concentration, and cryopreservation of the hPSCs for future use. These expanded cells exhibit high quality, normal karyotype, and the potential to differentiate into various cell types, supporting diverse clinical applications.
The traditional 2D culture systems, while informative, lack scalability and fail to meet the cell quantity demands cost-effectively. The transition to suspension culture systems offers a robust, controlled, and scalable alternative, aligning with current Good Manufacturing Practice (cGMP) guidelines. These systems leverage both aggregate-based and microcarrier-based 3D cultures to achieve high-density cell expansion. The use of microcarriers provides a larger surface area for growth, flexibility in matrix selection, and homogenous culture conditions, enabling efficient expansion of hPSCs.
The end-to-end platform for hPSC expansion represents a significant advancement in biotech manufacturing operations, offering a comprehensive solution from cell cultivation to cryopreservation. The platform’s microcarrier-based approach, coupled with xeno-free culture conditions, ensures the production of high-quality hPSCs suitable for various clinical indications. The scalability and automation of the platform streamline the manufacturing process, paving the way for large-scale production of therapeutic cells.
The L7™ TFO2 hPSC media, in combination with L7™ hPSC Matrix-coated microcarriers, has demonstrated remarkable support for hPSC growth and expansion in suspension cultures. The optimization of parameters such as microcarrier size, cell density, and flow rates has yielded high fold expansion of hPSCs without compromising cell yield or viability. The successful establishment of fluidized beds and concentration of cells using automated centrifugation devices like the kSep further enhances the efficiency and scalability of the manufacturing process.
Quality assessments post-harvest and post-concentration have confirmed the maintenance of hPSC characteristics, including morphology, marker expression, karyotype integrity, and pluripotency. The cryopreservation of expanded hPSCs post-concentration has proven to be a viable strategy for preserving cell integrity and viability, eliminating the need for extensive 2D seed trains. Thawed cryopreserved cells have shown successful recovery, retaining their hPSC characteristics and demonstrating the potential to be directly inoculated into bioreactors for subsequent expansion and differentiation.
In conclusion, the integration of innovative platforms, advanced technologies, and optimized processes has revolutionized human pluripotent stem cell manufacturing operations. The seamless transition from expansion to cryopreservation, coupled with automation and scalability, has paved the way for efficient and reliable production of therapeutic cells. The future of regenerative medicine and cell therapies hinges on such transformative approaches, ensuring the delivery of high-quality, clinically relevant cells for diverse applications.
Key Takeaways:
– The development of scalable cell production platforms is essential for bridging the gap between research and commercialization in stem-cell based therapies.
– Suspension culture systems, particularly microcarrier-based approaches, offer scalable and controlled environments for high-density cell expansion.
– Advanced technologies such as automated centrifugation devices streamline the concentration process post-harvest, enhancing efficiency and scalability.
– Cryopreservation of expanded hPSCs post-concentration eliminates the need for extensive 2D seed trains, offering a more streamlined and efficient manufacturing workflow.
– Quality assessments post-harvest, post-concentration, and post-cryopreservation confirm the maintenance of hPSC characteristics, ensuring the production of high-quality therapeutic cells.
Tags: automation, regenerative medicine, cell culture, downstream, filtration, cell therapy, bioreactor, cell therapies
Read more on pmc.ncbi.nlm.nih.gov